Barcelona, Spain-based Oryzon Genomics SA added José Gutiérrez-Ramos to the company's board as an independent director.
Gutiérrez-Ramos is the president and CEO of Synlogic Inc.
Meanwhile, three directors representing Najeti, a private investment fund that owns 20.54% of Oryzon's capital, have resigned from the company's board.
Following the changes, Oryzon's board is now composed of seven directors, with four as independent directors.
Oryzon develops therapies for cancer and neurodegenerative diseases.